
Opinion|Videos|November 5, 2024
Integrating VMS Treatment Into Comprehensive Women’s Health Management
Key Takeaways
- Hormone therapy for VMS requires careful evaluation of risks, especially in women with pre-existing conditions.
- Non-hormonal treatments and lifestyle modifications are vital in managing menopause-related symptoms.
Panelists discuss how to effectively integrate vasomotor symptom (VMS) treatment into comprehensive health management plans for women, taking into account the significant comorbidities associated with menopause, such as cardiovascular disease and osteoporosis.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- (FIFFICK) Considering the significant comorbidities often associated with menopause, such as cardiovascular disease and osteoporosis, how should VMS treatment be integrated into a broader health management plan for women?
Advertisement
Related to this article

A meta-analysis of HELIOS-B and CARDIO-TTRansform found gene silencers reduced death and CV events, driven by patients not taking stabilizers.

ApoB more directly reflects atherogenic particle burden than LDL-C, but missing outcome trials and assay variability still limit its routine use.

An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.

On National Latinx AIDS Awareness Day, experts outline HIV prevention gaps in Hispanic communities and how payers can ease PrEP access.

In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.

HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.

CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
3
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
4
5 Things to Know About the One Big Beautiful Bill Act
5

